Oncological therapy using anti-VEGF drugs and immunotherapy using anti-PD-1/PD-L1 drugs has changed the face of treatment of many cancers, significantly improving the achieved results, with relatively good tolerance. This evidence concerns the gene PDCD1 and cancer.